Mushroom Beta-Glucans and Gut Inflammation: IBD Research

Mushrooms & Inflammatory Bowel Disease

46 patients

In the only published human randomized trial of a mushroom extract specifically in Crohn's disease, 46 patients taking Agaricus blazei extract showed significantly reduced disease activity, fatigue, and improved quality of life compared to placebo.

Therkelsen et al., PLoS One, 2016

3 pathways

through which mushroom beta-glucans reduce gut inflammation

Human tissue

Reishi triterpenoids tested in actual Crohn's disease biopsy specimens

Microbiome-dependent

prebiotic pathway requires functional gut bacteria to complete the chain

Therkelsen et al., PLoS One, 2016

View as image ↗

Most coverage of mushrooms and gut health stays at the surface: polysaccharides support digestion, mushrooms are good for the microbiome, eat more fiber. What never gets explained is why mushroom beta-glucans interact with inflamed gut tissue differently from other dietary fibers, or why the same compound might produce stronger effects in someone with a healthy microbiome than in someone whose gut bacteria have been disrupted by years of active IBD. This article focuses on that deeper layer: the specific mechanisms through which mushroom beta-glucan gut inflammation IBD research has identified, the species with the most relevant evidence, and one important nuance about microbiome dependence that most sites skip entirely.

For broader context on how mushroom polysaccharides feed the gut microbiome in general, Mushrooms as Prebiotics: How They Feed Your Gut Bacteria covers that foundation. This article goes deeper on the IBD-specific evidence.

What Mushroom Beta-Glucans Actually Are (And Why the Branching Structure Matters)

The mushroom cell wall is built from two main structural materials. Chitin forms the rigid scaffold and is largely insoluble; it passes through the digestive system without much biological interaction. Beta-glucans are different. They are soluble polysaccharides: long chains of glucose molecules linked in a branching, three-dimensional configuration that dissolves in the gut and becomes biologically active.

The three-dimensional shape is what makes mushroom beta-glucans distinctive. The mushroom type follows a beta-1,3/1,6-glucan pattern, meaning the main glucose chain sprouts side branches at the 1,6 positions. Oat and barley beta-glucans use a different branching pattern (beta-1,3/1,4) that the human immune system registers differently. This structural difference matters because gut immune cells carry a receptor called Dectin-1 that was shaped by evolution to recognize the mushroom-type branching pattern specifically. Dectin-1 does not activate in the same way with oat beta-glucan.

That structural distinction is the foundational reason why mushroom beta-glucans engage the immune system differently from other dietary fibers, and why their effects in inflamed gut tissue have attracted specific IBD research interest.

A 2023 review by Wan and colleagues, published in Phytomedicine, identified three distinct mechanisms through which mushroom polysaccharides interact with gut immune cells and microbiota.^[1] The three routes operate independently, which means different mushroom species can reduce gut inflammation even when they work through entirely different molecular pathways.

Three Mechanisms, Not One: How Beta-Glucans Target IBD Inflammation

Beta-glucans are polysaccharides found in mushroom cell walls. In IBD research, they reduce gut inflammation through three pathways:

1. Dectin-1 receptor activation. Mushroom beta-glucans bind to Dectin-1 receptors on gut immune cells. When that binding occurs, the cells shift their output: anti-inflammatory IL-10 rises, and pro-inflammatory proteins TNF-α and IL-6 fall.

2. Prebiotic fermentation and short-chain fatty acid production. Beneficial gut bacteria ferment mushroom beta-glucans and produce short-chain fatty acids (SCFAs), primarily butyrate. Butyrate binds to receptors on colon wall cells called GPR41 and GPR43. When GPR41/43 are activated, they send an anti-inflammatory signal into the colon tissue.

3. NF-κB pathway suppression. NF-κB is the master inflammation switch inside gut cells. When it is activated, it turns on dozens of inflammation genes simultaneously. Multiple mushroom species contain compounds that directly block NF-κB activation, reducing inflammatory signaling independently of the microbiome.

Each pathway is independently supported by research and can function without the others.

The Immune Receptor Route: How Dectin-1 Converts Beta-Glucan Binding Into an Anti-Inflammatory Signal

When a mushroom beta-glucan molecule reaches the gut, the first structure it encounters is Dectin-1 on the surface of dendritic cells and macrophages. These are the immune patrol cells that line the intestinal wall and monitor everything passing through.

Dectin-1 is a pattern recognition receptor. It was shaped by evolution to detect fungal pathogens, but it responds to any molecule carrying the mushroom-type beta-1,3/1,6-glucan branching pattern. When Dectin-1 binds a beta-glucan molecule, it triggers a signaling cascade inside the immune cell that results in increased IL-10 production (the body's natural anti-inflammatory molecule) and reduced TNF-α output (one of the primary drivers of IBD inflammation).

This pathway is direct. No bacteria are needed. The beta-glucan arrives, binds Dectin-1, and the immune cell changes its behavior.

Wan and colleagues outlined the Dectin-1-TLR2 receptor signaling axis in their 2023 review, confirming it as one of three distinct modes of action by which mushroom polysaccharides engage gut immune biology.^[1] Zhao and colleagues, in a 2022 comprehensive review of mushroom polysaccharides and gut microbiota, confirmed that Dectin-1 activation specifically shifts gut immune populations toward anti-inflammatory phenotypes relevant to colitis.^[2]

In IBD, TNF-α is chronically elevated, and TNF-α-blocking biologics are a frontline treatment for moderate-to-severe disease. Dectin-1-mediated signaling does not produce the same magnitude of TNF-α reduction as biologic drugs. But it operates through a complementary, receptor-mediated route that does not require pharmaceutical intervention to initiate.

The Prebiotic Chain: Turkey Tail Is the Only Mushroom With Human Evidence for This Pathway

The second pathway runs through the microbiome, and Turkey Tail mushroom has the most direct human evidence for it.

Turkey Tail produces PSP (polysaccharopeptide), a beta-glucan-type prebiotic. In 2014, Pallav and colleagues ran a randomized study in 24 healthy volunteers comparing PSP to amoxicillin, an antibiotic that dramatically disrupts gut bacteria. PSP significantly increased Bifidobacterium and Lactobacillus populations in the gut while suppressing Clostridium and Staphylococcus growth.^[3] This is human evidence, not a mouse model, showing that a specific mushroom beta-glucan changes which bacteria thrive in the human gut.

The chain from that microbiota shift to reduced IBD inflammation runs as follows. More Bifidobacterium and Lactobacillus means more butyrate production. Butyrate is the primary fuel for colon cells and binds to GPR41 and GPR43 receptors in the colon wall. When those receptors are activated, they send an anti-inflammatory signal directly into colon tissue.

Pan and colleagues demonstrated this complete signaling chain in a 2023 study using Lion's Mane mycelium-derived polysaccharide in a mouse ulcerative colitis model. The polysaccharide modulated gut microbiota composition and specifically activated GPR41/43 receptors through increased SCFA production, establishing the prebiotic-to-receptor pathway as a distinct Lion's Mane anti-colitis mechanism.^[4] Notably, the Pan study used mycelium-derived polysaccharide, not fruiting body. Many commercial Lion's Mane supplements use mycelium, so this source specificity is worth noting.

For readers who want deeper coverage of Turkey Tail's microbiome research, Turkey Tail and Gut Bacteria: The Most-Studied Prebiotic Mushroom covers the full PSP evidence base. And How Mushrooms Change Your Gut Microbiome: Research Review maps the microbiome-modulation data across species.

The NF-κB Switch: Tested in Human Crohn's Disease Tissue, Not Just Mouse Models

NF-κB is a protein complex that lives inside cells and functions as the master inflammation switch. When it gets activated, it turns on dozens of inflammation genes at once, driving chronic production of TNF-α, IL-1β, and IL-8. In IBD, NF-κB is chronically overactive. Blocking it is one of the primary targets of both pharmaceutical and research interest in IBD.

Multiple mushroom species contain compounds that suppress NF-κB activation. What makes the evidence for this pathway stronger than most IBD mushroom research is that two studies used human tissue, not animals.

In 2015, Liu and colleagues applied Ganoderma lucidum (Reishi) triterpenoid extract directly to biopsy specimens from actual Crohn's disease patients. NF-κB signaling was downregulated in the human intestinal tissue, and three key inflammatory proteins (TNF-α, IL-1β, and IL-8) were measurably reduced in those cells.^[5] The cells came from people who had Crohn's disease. The Reishi extract demonstrably changed what those inflamed human cells were doing. That is a different class of evidence from a mouse colitis model.

Poria cocos (Fu Ling), a medicinal mushroom used in traditional Chinese medicine, adds more NF-κB data. Liu and colleagues showed in 2018 that Poria cocos polysaccharide CMP33 reduced TNF-α, IL-6, and IL-1β in a mouse IBD model via Akt/NF-κB pathway suppression, the same signaling route as Reishi.^[6]

In 2024, Zhang and colleagues confirmed Poria cocos polysaccharide's efficacy in a DSS-induced ulcerative colitis model, with mechanisms that included mucosal barrier reinforcement alongside NF-κB inhibition, one of the most recent entries in this field.^[7] The 2024 Zhang study has not appeared in any consumer-facing IBD resource prior to this article.

Lentinan and Colorectal Cancer Risk: The Shiitake Connection IBD Patients Rarely Hear About

Lentinan is the primary beta-glucan isolated from shiitake mushrooms (Lentinula edodes). Its anti-inflammatory mechanism is NF-κB-mediated: lentinan suppresses production of the inflammatory protein IL-8, which drives neutrophil recruitment to inflamed gut tissue.^[8]

What makes lentinan particularly relevant for IBD patients is a second finding in the same evidence base: lentinan shows antiproliferative effects on cell lines derived specifically from colitis-associated colorectal cancer.

This matters because IBD significantly elevates colorectal cancer risk. Patients with long-standing ulcerative colitis face meaningfully higher colorectal cancer rates compared to the general population. The chronically inflamed colon epithelium undergoes cellular changes over years that can progress toward malignancy. A compound that suppresses the inflammation driving those changes and also shows direct antiproliferative effects on the cancer cells that arise from that disease context occupies a potentially relevant position.

The Han 2019 review notes that the cancer data is from in vitro and animal studies, not clinical trials.^[8] Clinical implications remain speculative. But lentinan's relevance to IBD patients extends beyond simple anti-inflammation, and that dimension is absent from every competitor resource on this topic.

The Only Human RCT in IBD: 46 Crohn's Patients, One Mushroom Extract, One Meaningful Result

Everything covered so far in this article rests on animal models or human tissue studies. What IBD research needs, and largely does not yet have, is human randomized controlled trials in living patients. There is, to date, exactly one published RCT of any mushroom extract specifically in patients with inflammatory bowel disease.

In 2016, Therkelsen and colleagues enrolled 46 Crohn's disease patients in a randomized, single-blinded, placebo-controlled study. Patients received AndoSan, a commercially produced Agaricus blazei Murrill-based extract, for 12 weeks. The primary outcomes were Crohn's disease activity index (CDAI) scores, fatigue levels, and quality of life.^[9]

The AndoSan group showed significantly reduced CDAI scores compared to placebo at study end. They also reported significantly less fatigue and improved quality of life. Both effects reached statistical significance.

A few honest limitations: the study was single-blinded, not double-blinded. The researchers knew which patients received AndoSan versus placebo. This is a weaker design than double-blinding and is the study's most-cited limitation. The sample size of 46 is small relative to the hundreds required for IBD drug approvals. AndoSan is a specific commercial product; the results cannot be generalized to other Agaricus blazei preparations or other mushroom species.

What the Therkelsen trial establishes is that a randomized human study of a mushroom polysaccharide extract in Crohn's disease can show a measurable, statistically significant reduction in disease activity. The trial was published a decade ago. No larger or better-powered follow-up trial has appeared since.

For the full landscape of human versus animal mushroom evidence in IBD across species, Mushrooms for IBD: Can They Help Crohn's and Ulcerative Colitis? maps the evidence tiers. For the species-by-species anti-inflammatory breakdown, Anti-Inflammatory Mushrooms for Inflammatory Bowel Disease covers that ground. And for the full mechanistic picture, Mushrooms and IBD: Anti-Inflammatory Mechanisms in Crohn's and Ulcerative Colitis goes deeper on how different species target different parts of the inflammatory cascade.

The Catch: Beta-Glucan's Anti-Inflammatory Effect Depends on the Gut Bacteria You Already Have

The prebiotic pathway described above (mushroom beta-glucans feeding Bifidobacterium, which produces butyrate, which activates GPR41/43 receptors) does not operate in isolation. It depends entirely on having enough functional gut bacteria to complete the fermentation step.

In 2019, Liao and colleagues tested beta-glucan supplementation in two groups of mice: conventionally housed animals with intact gut microbiomes and germ-free animals with no gut bacteria. In the germ-free group, beta-glucan's anti-colitis effects were significantly blunted. Without bacteria to ferment the polysaccharide, SCFA production did not occur, and the downstream GPR41/43 signaling was absent.^[10]

The Liao study used oat-derived beta-glucan, not mushroom beta-glucan specifically. But the shared fermentation mechanism means the principle applies across sources: whenever gut bacteria are too depleted to ferment dietary polysaccharides efficiently, Pathway 2 is compromised regardless of the source.

IBD is closely associated with gut dysbiosis. Patients with active Crohn's disease and ulcerative colitis typically show depleted populations of Ruminococcaceae and Bifidobacterium alongside elevated Proteobacteria. The more severe the dysbiosis, the more compromised Pathway 2 becomes.

This does not mean beta-glucans are ineffective in IBD. Pathway 1 (Dectin-1) and Pathway 3 (NF-κB) operate without microbiome involvement and remain intact regardless of bacterial populations. But the full three-pathway effect is only achieved when gut bacteria are healthy enough to participate in the fermentation step. Most animal colitis studies test mushroom polysaccharides in conventionally housed mice with intact microbiomes. Translating those results to IBD patients, whose microbiomes are characteristically disrupted, requires that nuance.

The Bottom Line

Mushroom beta-glucans reduce gut inflammation through three distinct pathways: direct Dectin-1 immune receptor signaling, prebiotic fermentation that increases SCFA-producing bacteria, and NF-κB suppression. Human evidence is limited but meaningful: Agaricus blazei is the only species tested in a human RCT in IBD, Reishi triterpenoids have been tested in actual Crohn's disease biopsy tissue, and Turkey Tail PSP has direct human evidence for gut bacteria modulation. The 2024 Poria cocos study adds the most recent data. A critical nuance: the prebiotic pathway depends on having functional gut bacteria to complete the fermentation chain, which may be compromised in IBD patients with severe dysbiosis.

Frequently Asked Questions

What is beta-glucan and how does it work?

Beta-glucans are soluble polysaccharides found in mushroom cell walls: chains of glucose molecules linked in a branching three-dimensional structure. Mushroom beta-glucans specifically bind to Dectin-1 receptors on gut immune cells, triggering anti-inflammatory signaling that raises IL-10 and reduces TNF-α. They also act as prebiotics: beneficial gut bacteria ferment them, produce butyrate and other short-chain fatty acids, and those fatty acids bind GPR41/43 receptors in the colon wall to generate anti-inflammatory signals. A third mechanism is direct NF-κB pathway suppression, which blocks the master inflammation switch inside gut cells independently of the microbiome. Mushroom beta-glucans work through all three routes simultaneously.

Do beta-glucans reduce intestinal inflammation?

In research settings, yes, though with important caveats about evidence quality. Multiple animal studies show mushroom beta-glucans reduce colon inflammation in induced colitis models across at least six species. Human evidence is more limited: one randomized trial of Agaricus blazei extract in Crohn's disease (46 patients) found significantly reduced disease activity scores and fatigue compared to placebo (Therkelsen et al., 2016). Reishi triterpenoids tested in actual human Crohn's disease biopsy tissue reduced inflammatory markers in those cells (Liu et al., 2015). No large human clinical trial has been completed for any specific mushroom beta-glucan in IBD.

Which mushrooms have the most beta-glucan?

Turkey Tail is among the richest sources of a specific beta-glucan type called PSP (polysaccharopeptide), and its prebiotic effects on human gut bacteria have been tested directly in a clinical study. Reishi, Shiitake (via lentinan), Lion's Mane, and Poria cocos all have documented beta-glucan fractions with IBD-relevant research. Beta-glucan content varies substantially by species, extraction method, and whether the product uses fruiting body or mycelium. Commercial mushroom extracts standardized to beta-glucan percentage specify that on the label; raw mushroom powder typically does not quantify it.

How do beta-glucans help the gut?

Beta-glucans help the gut through three independently documented mechanisms. First, they bind Dectin-1 receptors on gut immune cells and shift those cells toward anti-inflammatory output, raising IL-10 and lowering TNF-α. Second, beneficial gut bacteria ferment beta-glucans and produce butyrate and other short-chain fatty acids. Those fatty acids fuel colon cells and activate GPR41/43 receptors that reduce mucosal inflammation. Third, some mushroom compounds directly block NF-κB activation, the signaling process that switches on inflammation genes inside gut cells. Because these three pathways are independent, different mushroom species can reduce gut inflammation even when they work through entirely different mechanisms.

Is beta-glucan good for IBD?

The research is promising but not yet conclusive for human IBD. The one human randomized trial in Crohn's disease (46 patients, Agaricus blazei extract) showed significant reductions in disease activity and fatigue. Animal studies across multiple species consistently show anti-colitis effects. Human Crohn's disease biopsy tissue data confirms that Reishi compounds reduce inflammatory markers in actual inflamed mucosa. A key nuance: beta-glucan's prebiotic effects depend on having enough healthy gut bacteria to complete the fermentation pathway. In IBD patients with severe dysbiosis, that pathway may be compromised, limiting how much of the three-mechanism benefit they receive. No mushroom beta-glucan has been approved or established as an IBD treatment.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3RTHM-00630·Pallav, Kumar et al. (2014). “Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial..” Gut microbes.Study breakdown →PubMed →↩
4. 4. Source details for this reference are not yet available.
5. 5RTHM-00719·Liu, Changda et al. (2015). “Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling..” Inflammatory bowel diseases.Study breakdown →PubMed →↩
6. 6RTHM-00978·Liu, Xiaofei et al. (2018). “The protective effects of Poria cocos-derived polysaccharide CMP33 against IBD in mice and its molecular mechanism..” Food & function.Study breakdown →PubMed →↩
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9RTHM-00451·Therkelsen, Stig Palm et al. (2016). “Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn's Disease in a Randomized Single-Blinded Placebo Controlled Study..” PloS one.Study breakdown →PubMed →↩
10. 10. Source details for this reference are not yet available.